Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−34.92 USD
−94.82 M USD
2.91 M USD
1.51 M
About Singular Genomics Systems, Inc.
Sector
Industry
CEO
Andrew Spaventa
Website
Headquarters
San Diego
Founded
2016
FIGI
BBG010WX4GM6
Singular Genomics Systems, Inc. engages in the development and commercialization of proprietary sequencing solutions. It develops two integrated solutions: G4 Instrument and PX Instrument. The G4 Instrument operates as a benchtop next generation sequencer designed to produce fast and accurate genetic sequencing results. The PX Instrument combines single cell and spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company was founded by Eli Glezer, David Barker and Andrew Spaventa in June 2016 and is headquartered in San Diego, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of OMIC is 19.35 USD — it has increased by 0.47% in the past 24 hours. Watch Singular Genomics Systems, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Singular Genomics Systems, Inc. stocks are traded under the ticker OMIC.
OMIC stock has fallen by −3.25% compared to the previous week, the month change is a −9.58% fall, over the last year Singular Genomics Systems, Inc. has showed a 57.32% increase.
OMIC reached its all-time high on Jun 2, 2021 with the price of 1,001.10 USD, and its all-time low was 5.34 USD and was reached on Sep 11, 2024. View more price dynamics on OMIC chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
OMIC stock is 2.08% volatile and has beta coefficient of 6.13. Track Singular Genomics Systems, Inc. stock price on the chart and check out the list of the most volatile stocks — is Singular Genomics Systems, Inc. there?
Today Singular Genomics Systems, Inc. has the market capitalization of 48.60 M, it has decreased by −2.28% over the last week.
Yes, you can track Singular Genomics Systems, Inc. financials in yearly and quarterly reports right on TradingView.
Singular Genomics Systems, Inc. is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
OMIC earnings for the last quarter are −6.72 USD per share, whereas the estimation was −8.24 USD resulting in a 18.45% surprise. The estimated earnings for the next quarter are −8.10 USD per share. See more details about Singular Genomics Systems, Inc. earnings.
Singular Genomics Systems, Inc. revenue for the last quarter amounts to 406.00 K USD, despite the estimated figure of 950.00 K USD. In the next quarter, revenue is expected to reach 1.77 M USD.
OMIC net income for the last quarter is −16.80 M USD, while the quarter before that showed −21.25 M USD of net income which accounts for 20.98% change. Track more Singular Genomics Systems, Inc. financial stats to get the full picture.
No, OMIC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 26, 2024, the company has 265.00 employees. See our rating of the largest employees — is Singular Genomics Systems, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Singular Genomics Systems, Inc. EBITDA is −86.16 M USD, and current EBITDA margin is −3.22 K%. See more stats in Singular Genomics Systems, Inc. financial statements.
Like other stocks, OMIC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Singular Genomics Systems, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Singular Genomics Systems, Inc. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Singular Genomics Systems, Inc. stock shows the neutral signal. See more of Singular Genomics Systems, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.